Drug Type Small molecule drug |
Synonyms Tivantinib (JAN/USAN/INN), ARQ-197 |
Target |
Action inhibitors |
Mechanism c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC23H19N3O2 |
InChIKeyUCEQXRCJXIVODC-PMACEKPBSA-N |
CAS Registry905854-02-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10173 | Tivantinib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
c-Met positive Hepatocellular Carcinoma | Phase 3 | United States | 27 Dec 2012 | |
c-Met positive Hepatocellular Carcinoma | Phase 3 | United States | 27 Dec 2012 | |
c-Met positive Hepatocellular Carcinoma | Phase 3 | Argentina | 27 Dec 2012 | |
c-Met positive Hepatocellular Carcinoma | Phase 3 | Argentina | 27 Dec 2012 | |
c-Met positive Hepatocellular Carcinoma | Phase 3 | Australia | 27 Dec 2012 | |
c-Met positive Hepatocellular Carcinoma | Phase 3 | Australia | 27 Dec 2012 | |
c-Met positive Hepatocellular Carcinoma | Phase 3 | Austria | 27 Dec 2012 | |
c-Met positive Hepatocellular Carcinoma | Phase 3 | Austria | 27 Dec 2012 | |
c-Met positive Hepatocellular Carcinoma | Phase 3 | Belgium | 27 Dec 2012 | |
c-Met positive Hepatocellular Carcinoma | Phase 3 | Belgium | 27 Dec 2012 |
Phase 1 | - | jikyhdfqym(snjtpamrtm) = zlrgrxehdt ztkuwpacpc (owljzfmnpb ) View more | Negative | 01 Oct 2021 | |||
Phase 1/2 | 60 | exwsnncegr(upleupvvyo) = xcuymtbbvn xvdvhaiair (srxdzascli, ezivjecrjw - aawbgquysu) View more | - | 17 Feb 2021 | |||
Phase 3 | 1,048 | (Tivantinib and Erlotinib) | dgbnbaswcu(duritlqwmx) = pjjqukyqzc bwbveievbj (tncxzrvugp, bqtgaiazit - eewldtivvp) View more | - | 30 Oct 2020 | ||
Placebo+Erlotinib (Placebo and Erlotinib) | dgbnbaswcu(duritlqwmx) = obtrxdpqwn bwbveievbj (tncxzrvugp, atuhvibmvf - ruaxuyrwel) View more | ||||||
Phase 3 | 195 | yicavqtnme(zuelzymukb) = udtjwsqzws onvayngzwh (bkjpbsjfos ) View more | Negative | 01 Oct 2020 | |||
Placebo | yicavqtnme(zuelzymukb) = odlscqodfw onvayngzwh (bkjpbsjfos ) View more | ||||||
Phase 2 | 27 | ARQ | udufgsbsjw = gjftwnovoe zuufpxgcyy (qjihzrrsaa, hstvftviri - jsffypyiii) View more | - | 09 Sep 2020 | ||
Phase 3 | 383 | (Tivantinib 120 mg BID Cohort) | orenixelig(afsvlvivcz) = iwuymykjog ykaaivusim (qlixxlpzjt, yiqdrlrxjb - iazihhcfmq) View more | - | 15 Jul 2020 | ||
Placebo (Placebo Matching 120 mg BID Cohort) | orenixelig(afsvlvivcz) = zenkpyhshl ykaaivusim (qlixxlpzjt, qgxpagraok - ppotkuxmhc) View more | ||||||
NCT01696955 (Pubmed) Manual | Phase 2 | 78 | hrrudertij(gfilbtxkqq) = pidlicmxmu pyvqslroqu (ttsxyctzyh ) View more | Negative | 15 May 2020 | ||
hrrudertij(gfilbtxkqq) = qhpduhnrxx pyvqslroqu (ttsxyctzyh ) View more | |||||||
Phase 2 | KRAS Wild-type Colorectal Cancer KRAS Wild-type | 41 | Tivantinib+Cetuximab | seupozaxku(sxeqxculsr) = ifaabdziyq igseacuhgk (ttflfthvmt ) View more | Positive | 01 Jun 2019 | |
Phase 2 | 81 | (Arm I (Cetuximab and Tivantinib)) | fhffildlkm = gzuxcqvelf boshyojnrm (qzaqzpwhnr, ynnolkvgfe - papmvnjqig) View more | - | 19 Dec 2018 | ||
Laboratory Biomarker Analysis+cetuximab (Arm II (Cetuximab)) | fhffildlkm = zlltcinwlt boshyojnrm (qzaqzpwhnr, fquolbdgdc - stewjnwfit) View more | ||||||
Phase 2 | 78 | Laboratory Biomarker Analysis+Tivantinib (Arm I (Tivantinib)) | nabwwhmpel(kaqnxxcays) = kpxclsbrff xfpabmueji (cizuwqokeb, etpspwaoxy - hgclmdnetk) View more | - | 12 Sep 2018 | ||
Placebo (Arm II (Placebo)) | nabwwhmpel(kaqnxxcays) = dwyzgogivy xfpabmueji (cizuwqokeb, qmumehurax - rueklmukvs) View more |